Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of its blockbuster GLP-1 medication semaglutide. Novo Nordisk alleges in its lawsuit that Hims & Hers has infringed on its patent by selling compounded Ozempic and Wegovy…
previous post